Health Discovery Corporation (OTCBB: HDVY) announced today that Nitesh Chawla, Ph.D., Assistant Professor in the Department of Computer Science and Engineering and Co-Director of the Interdisciplinary Center for Network Science and Applications at the University of Notre Dame, South Bend, Ind., has joined the Health Discovery Corporation’s Science Advisory Board. Dr. Chawla is an expert in data mining and machine learning. “The addition of Dr. Nitesh Chawla to our Science Advisory Board brings a major intellectual resource and additional expertise to our company,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We’re thrilled to have Dr. Chawla join our team of scientists,” said Dr. Barnhill. “Health Discovery Corporation has an impressive suite of techniques and applications in personalized medicine, and a highly prestigious Science Advisory Board. I am honored and humbled to become a part of it,” said Dr. Chawla. Dr. Chawla is a welcomed Member of HDC's Science Advisory Team which includes among others Kary Mullis, Ph.D., winner of the Nobel Prize for Chemistry (1993), Vladmir Vapnik, Ph.D., creator of Support Vector Machines and winner of the prestigious Humboldt Research Award—for his academic achievements—by the Alexander-von-Humboldt-Foundation, and Isabelle Guyon, Ph.D., co-inventor of the first patent for Support Vector Machines. A prodigious researcher and writer, Dr. Chawla has authored or co-authored over ninety papers in journals, books, conferences, and workshops. His papers have been cited over 1,400 times, according to Google Scholar. He has received grants or sponsored research from organizations such as the National Science Foundation , the National Institute of Justice, and the Army Research Labs. He and his research team of graduate and undergraduate students have received numerous awards and honors for their research, including the outstanding dissertation award, research excellence award, best papers at conferences, students’ research posters at Notre Dame Research symposia, and won first place in the challenge organized at the Neural Information Processing Society (NIPS) conference. Dr. Chawla has also been noted for his teaching accomplishments, receiving the National Academy of Engineers New Faculty Fellowship and Outstanding Undergraduate Teacher Award in 2008.
A frequent national and international guest lecturer, Dr. Chawla has presented almost thirty lectures hosted by universities in the US, Europe, and Asia; national labs and research centers; international conferences; and companies.Dr. Chawla received his B.E., Computer Science from the University of Pune, India, 1997, his M.S. in Computer Science from the University of South Florida, 1999, and his Ph.D. in Computer Science and Engineering from the University of South Florida in 2002. After Ph.D., and prior to joining Notre Dame, Dr. Chawla was a Senior Risk Modeling Manager at Canadian Imperial Bank of Commerce, Toronto, Canada. Additional information about Dr. Chawla is available at http://www.nd.edu/~nchawla. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.